切换至 "中华医学电子期刊资源库"
高级检索
中华移植杂志(电子版)

中华移植杂志(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 118 -123. doi: 10.3877/cma.j.issn.1674-3903.2020.02.014

所属专题： 文献；

荟萃分析

HCV感染与肾移植后糖尿病关系的荟萃分析
李超1, 刘炎忠1, 刘志佳1, 柏宏伟1, 药晨1, 谢晓媚1, 李钢1, 余飞1, 解俊杰1, 石炳毅1,†()   
  1. 1. 100091　北京，解放军总医院第八医学中心器官移植研究所；100091　北京，北京市器官移植和免疫调节重点实验室
  • 收稿日期:2019-09-01 出版日期:2020-04-25
  • 通信作者: 石炳毅
  • 基金资助:
    国家自然科学基金(81570680)

Relationship between hepatitis C virus infection and post transplantation diabetes mellitus: a meta-analysis

Chao Li1, Yanzhong Liu1, Zhijia Liu1, Hongwei Bai1, Chen Yao1, Xiaomei Xie1, Gang Li1, Fei Yu1, Junjie Xie1, Bingyi Shi1,†()   

  1. 1. Organ Transplant Institute, the 8th Medical Center of Chinese PLA General Hospital, Beijing 100091, China; Beijing Key Laboratory of Organ Transplant and Immune Regulation, Beijing 100091, China
  • Received:2019-09-01 Published:2020-04-25
  • Corresponding author: Bingyi Shi
  • About author:
    Corresponding author: Shi Bingyi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李超, 刘炎忠, 刘志佳, 柏宏伟, 药晨, 谢晓媚, 李钢, 余飞, 解俊杰, 石炳毅. HCV感染与肾移植后糖尿病关系的荟萃分析[J]. 中华移植杂志(电子版), 2020, 14(02): 118-123.

Chao Li, Yanzhong Liu, Zhijia Liu, Hongwei Bai, Chen Yao, Xiaomei Xie, Gang Li, Fei Yu, Junjie Xie, Bingyi Shi. Relationship between hepatitis C virus infection and post transplantation diabetes mellitus: a meta-analysis[J]. Chinese Journal of Transplantation(Electronic Edition), 2020, 14(02): 118-123.

目的

应用荟萃分析系统评价HCV感染是否为肾移植后糖尿病(PTDM)的相关危险因素。

方法

系统检索中国期刊全文数据库、中国生物医学数据库、PubMed数据库、Embase数据库、Google scholar和Web of science database截至2019年12月公开发表的相关文献。应用Stata 15.1统计软件使用随机效应模型进行荟萃分析，计算相对危险度(RR)。

结果

共纳入22篇文献，包含129 981例肾移植受者。荟萃分析结果显示，HCV感染的肾移植受者术后发生PTDM的风险为非HCV感染者的2.5倍(RR＝2.50, 95%CI: 1.95～3.20, P<0.001)。在亚洲、高加索和美洲人种中，HCV感染均为肾移植术后PTDM的危险因素。

结论

HCV感染是促进肾移植术后发生PTDM的危险因素，感染者需尽早进行清除HCV的相关治疗。

关键词: 肾移植, 移植后糖尿病, 危险因素, 荟萃分析
Objective

To use a meta-analysis system to evaluate whether hepatitis C virus (HCV) infection is a risk factor for post transplantation diabetes mellitus (PTDM) in kidney transplant recipients.

Methods

All the papers published up to December 2019 in Chinese journal full-text database, Chinese biomedical database, PubMed database, Embase database, Google scholar and Web of science database had been systematically searched. A meta-analysis was performed using a random effects model using Stata 15.1 software to calculate relative risk (RR).

Results

A total of 22 articles including 129 981 kidney transplant recipients were included. The results of meta-analysis showed that HCV infected recipients did have an relative risk of PTDM by about 2.5 times to non HCV infected recipients (RR=2.50, 95%CI: 1.95-3.20, P<0.001). Subgroup analysis based on race found that HCV infection was a significant risk factor for PTDM after kidney transplantation in Asian, Caucasian, and American races.

Conclusions

HCV infection is a risk factor that promotes PTDM in recipients after kidney transplantation. Infected recipients should be treated as soon as possible to elimate HCV.

Key words: Kidney transplantation, Post transplantation diabetes mellitus, Risk factor, Meta-analysis
图1 文献检索流程图
表1 纳入文献的基本特征
纳入研究 发表年份(年) 国家 人种 肾移植受者例数(例) HCV阳性[例(%)] 移植后糖尿病[例(%)] 随访时间(月) 文献质量评分(分)
Gursoy等[12] 2000 土耳其 高加索 247 40(16) 40(16) 39 8
Hirakauva等[27] 2002 巴西 美洲 227 227(77) 33(15) 72 7
Baid等[22] 2002 美国 美洲 114 18(16) 7(39) 12 6
Yildiz等[11] 2002 土耳其 高加索 86 47(55) 43(50) 24 6
Gentil等[13] 2002 西班牙 高加索 354 177(50) 28( 8) 44 7
Kasiske等[20] 2003 美国 美洲 11 659 658( 6) 2 798(24) 48 8
Gentil等[23] 2003 西班牙 高加索 570 123(23) 55(10) 95.6 7
López Hidalgo等[25] 2004 塞维利亚 高加索 325 94(29) 72(22) 18 6
Sens等[14] 2004 巴西 美洲 50 25(50) 9(18) 29 8
Foo等[15] 2004 马来西亚 亚洲 316 89(28) 42(13) 125 6
Gourishankar等[16] 2004 加拿大 高加索 386 11( 3) 35(10) 44 6
Bloom等[10] 2005 美国 美洲 427 71(17) 63(15) 41 6
Rodrigo等[21] 2005 西班牙 高加索 73 5( 7) 20(27) 108 6
Sezer等[19] 2006 土耳其 高加索 204 24(12) 26(13) 21.6 6
Shah等[30] 2006 美国 美洲 15 309 646( 4) 1 531(10) 10 8
Kamar等[24] 2007 法国 高加索 527 19( 4) 37( 7) 24 6
Guleria等[26] 2008 印度 亚洲 155 9( 6) 26(18) 16 6
Liu等[4] 2009 中国 亚洲 195 16( 8) 29(15) 12 6
Chen等[17] 2013 中国 亚洲 428 45(11) 87(20) 67 5
Wang等[18] 2015 中国 亚洲 128 13(10) 51(40) 12 5
Santos等[29] 2018 美国 美洲 97 644 3 850( 4) 无数据 60 8
Liang等[28] 2019 中国 亚洲 557 41( 7) 120(22) 96 7
图2 HCV感染与肾移植后糖尿病荟萃分析森林图
图3 HCV感染与肾移植后糖尿病根据随访时间的亚组分析
图4 HCV感染与肾移植后糖尿病荟萃分析漏斗图
[1]
周代会，唐怡. 肾移植患者HCV感染的临床治疗研究进展[J]. 肝脏，2018, 23(8)：730-733.
[2]
Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody and survival after renal transplantation: meta analysis of observational studies[J]. Am J Transplant, 2005, 5(6)：1452-1461.
[3]
Fernandes AR, Laranjinha IJ, Birne R, et al. HCV-infected renal transplant recipients：our experience before the availability of new antiviral drugs[J]. Int J Organ Transplant Med, 2017, 8(2)：104-109.
[4]
刘航，史屹，沈中阳. 肾移植术后新发糖尿病的危险因素及其对动脉僵硬度的影响[J]. 中华器官移植杂志，2009, 30(7)：415-418.
[5]
Khalili M, Lim WJ, Bass N, et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection[J]. Liver Transpl, 2004, 10(3): 349-355.
[6]
王红英. 关于丙肝病毒感染并发2型糖尿病的临床研究[J]. 心血管病防治知识(学术版), 2014, (2)：136-138.
[7]
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology(MOOSE)group[J]. JAMA, 2000, 283(15)：2008-2012.
[8]
Panesar SS, Athanasiou T, Nair S, et al. Early outcomes in the elderly: a meta- analysis of 4921 patients undergoing coronary artery bypass grafting-comparison between off-pump and on-pump techniques[J]. Heart, 2006, 92(12)：1808-1816.
[9]
Athanasiou T, Al-Ruzzeh S, Kumar P, et al. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients[J]. Ann Thorac Surg, 2004, 77(2)：745-753.
[10]
Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list[J]. Am J Transplant, 2005, 5(1): 139-144.
[11]
Yildiz A, Tutuncu Y, Yazici H, et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients[J]. Transplantation, 2002, 74(8)：1109-1113.
[12]
Gursoy M, Guvener N, Koksal R, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients[J]. Transplant Proc, 2000, 32(3): 561-562.
[13]
Gentil MA, Luna E, Rodriguez-Algarra G, et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C[J]. Nephrol Dial Transplant, 2002, 17(5)：887-891.
[14]
Sens YAS, Silva VDST, Malafronte P, et al. Post-transplant diabetes mellitus in renal transplant patients with hepatitis C virus[J]. Transplant Proc, 2004, 36(4)：886-888.
[15]
Foo SM, Wong HS, Morad Z. Risk factors and incidence of posttransplant diabetes mellitus in renal transplant recipients[J]. Transplant Proc, 2004, 36(7)：2139-2140.
[16]
Gourishankar S, Jhangri GS, Tonelli M, et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience[J]. Am J Transplant, 2004, 4(11)：1876-1882.
[17]
陈敏灵，张尧，于明香，等. 肾移植术后糖尿病的发病及其危险因素分析[J]. 中华内分泌代谢杂志，2013, 29(9)：750-755.
[18]
王英吉，狄文佳，孙勤，等. 肾移植术后糖尿病相关危险因素[J]. 肾脏病与透析肾移植杂志，2015, 24(1)：21-25.
[19]
Sezer S, Bilgic A, Uyar M, et al. Risk factors for development of posttransplant diabetes mellitus in renal transplant recipients[J]. Transplant Proc, 2006, 38(2)：529-532.
[20]
Schnitzler M, Kasiske BL, Snyder JJ, et al. Diabetes mellitus after kidney transplantation in the United States [1] (multiple letters)[J]. Am J Transplant, 2003, 3(10)：1318-1319.
[21]
Rodrigo E, De Cos MA, Fernández-Fresnedo G, et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus[J]. Transplant Proc, 2005, 37(9)：3819-3820.
[22]
Baid S, Tolkoff-Rubin N, Farrell ML, et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: Role of hepatitis C infection[J]. Transplant Proc, 2002, 34(5)：1771-1773.
[23]
Gentil MA, López M, González-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: Influence of new immunosuppression protocols[J]. Transplant Proc, 2003, 35(5)：1748-1750.
[24]
Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: A French multicentre observational study[J]. Nephrol Dial Transplant, 2007, 22(7)：1986-1993.
[25]
López Hidalgo R, Gentil MA, Acosta D, et al. Asociación entre diabetes mellitus y hepatitis C en trasplante renal[J]. Nefrologia, 2004, 24(6)：572-578.
[26]
Guleria S, Kamboj M, Chatterjee A, et al. Generic tacrolimus (Pan Graf) in renal transplantation: An experience of 155 recipients in India[J]. Transplant Proc, 2008, 40(7)：2237-2239.
[27]
Hirakauva EY, Ferraz MLG, Perez RM, et al. Prevalence of diabetes mellitus in renal transplant patients with hepatitis B or C virus infection[J]. Transplant Proc, 2002, 34(8)：3220-3222.
[28]
Liang J, Lv C, Chen M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5)：370-378.
[29]
Santos AH, Chen C, Casey MJ, et al. New-onset diabetes after kidney transplantation: Can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology？[J]. Nephrol Dial Transplant, 2018, 33(1)：177-184.
[30]
Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation[J]. Transplantation, 2006, 82(12)：1673-1676.
[31]
Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group[J]. Transplantation, 2000, 69(5)：875-880.
[32]
Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years[J]. Transplantation, 2001, 72(2): 245-250.
[33]
Margreiter A. A prospective, randomized multicentre study to compare the efficacy and safety of tacrolimus and cyclosporin microemulsion in renal transplantation[J]. Transplantation, 69(Suppl 8)：S112-S113.
[34]
Xie L, Tang W, Wang X, et al. Pretransplantation risk factors associated with new-onset diabetes after living-donor kidney transplantation[J]. Transplant Proc, 2016, 48(10)：3299-3302.
[35]
Gentil MA, Lopez M, Gonzalez-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: influence of new immunosuppression protocols[J]. Transplant Proc, 2003, 35(5)：1748-1750.
[36]
杨进，方芳，杨富，等. 肾移植术后新发糖尿病：危险因素的回顾性分析[J]. 中国组织工程研究，2017, 21(20)：3275-3280.
[37]
Siraj ES, Abacan C, Chinnappa P, et al. Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients[J]. Transplant Proc, 2010, 42(5)：1685-1689.
[38]
Hjelmesæth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance[J]. Nephrol Dial Transplantation, 2001, 16(4)：829-835.
[39]
Bergrem HA, Valderhaag TG, Hartmann A, et al. Glucose tolerance before and after renal transplantation[J]. Nephrol Dial Transplant, 2010, 25(3)：985-992.
[40]
Maldonado F, Tapia G, Ardiles L. Early hyperglycemia: a risk factor for posttransplant diabetes mellitus among renal transplant recipients[J]. Transplant Proc, 2009, 4l(6)：2664-2667.
[41]
Kaplan NM, Palmer BF, Mora PF. Post-transplantation diabetes mellitus[J]. Am J Med Sci, 2005, 329(2)：86-94.
[42]
Kurzawski M, Dziewanowski K, Droździk M. Analysis of type 2 diabetes mellitus genetic risk factors in relation to new onset diabetes after transplantation in renal transplant recipients medicated with tacrolimus[J]. Pharmacological Reports Pr, 2013, 65(1)：1-11.
[1] 刘欢颜, 华扬, 贾凌云, 赵新宇, 刘蓓蓓. 颈内动脉闭塞病变管腔结构和血流动力学特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 809-815.
[2] 马艳波, 华扬, 刘桂梅, 孟秀峰, 崔立平. 中青年人颈动脉粥样硬化病变的相关危险因素分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 822-826.
[3] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[4] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[5] 陈旭渊, 罗仕云, 李文忠, 李毅. 腺源性肛瘘经手术治疗后创面愈合困难的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 82-85.
[6] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[7] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[8] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[9] 王秀, 王义国. 乌司奴单抗治疗克罗恩病肛周瘘管的有效性和安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 514-519.
[10] 侯超, 潘美辰, 吴文明, 黄兴广, 李翔, 程凌雪, 朱玉轩, 李文波. 早期食管癌及上皮内瘤变内镜黏膜下剥离术后食管狭窄的危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 383-387.
[11] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[12] 陆猛桂, 黄斌, 李秋林, 何媛梅. 蜂蛰伤患者发生多器官功能障碍综合征的危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1010-1015.
[13] 李达, 张大涯, 陈润祥, 张晓冬, 黄士美, 陈晨, 曾凡, 陈世锔, 白飞虎. 海南省东方市幽门螺杆菌感染现状的调查与相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 858-864.
[14] 李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[15] 孟科, 李燕, 闫婧爽, 闫斌. 胶囊内镜胃通过时间的影响因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 671-675.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号